Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.

Cancer immunology, immunotherapy : CII - 1 Dec 2016

Wang Wei, Erbe Amy K, Gallenberger Mikayla, Kim KyungMann, Carmichael Lakeesha, Hess Dustin, Mendonca Eneida A, Song Yiqiang, Hank Jacquelyn A, Cheng Su-Chun, Signoretti Sabina, Atkins Michael, Carlson Alexander, Weiss Jonathan M, Mier James, Panka David, McDermott David F, Sondel Paul M

Abstract excerpt

NK cells play a role in many cancer immunotherapies. NK cell activity is tightly regulated by killer immunoglobulin-like receptor (KIR) and KIR-ligand interactions. Inhibitory KIR-ligands have been identified as HLA molecules, while activating KIR-ligands are largely unknown. Individuals that have not inherited the corresponding KIR-ligand for at least one inhibitory KIR gene are termed the "KIR-ligand missing"...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Renal Cell

Share to Genotype

Share to Interleukin-2

Share to Ligands

Share to Receptors, KIR

Source

Open in PubMed Open full text

Identifiers

PMID: 27695964
DOI: 10.1007/s00262-016-1904-8
PMCID: PMC5123674

Genes

IL2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.PMID 27695964Read ↗

KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.Semantic proximity Read ↗

Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.Semantic proximity Read ↗

Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.Semantic proximity Read ↗

Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia.Semantic proximity Read ↗

Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.Semantic proximity Read ↗

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.Semantic proximity Read ↗

No impact of KIR-ligand mismatch on allograft outcome in HLA-compatible kidney transplantation.Semantic proximity Read ↗

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.Semantic proximity Read ↗

Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.Semantic proximity Read ↗

FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

The Activating Human NK Cell Receptor KIR2DS2 Recognizes a β2-Microglobulin–Independent Ligand on Cancer CellsSemantic proximity Read ↗

Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.